Printer Friendly

DURA PHARMACEUTICALS SIGNS LETTER OF INTENT TO SELL DEVICE DIVISION TO PARI RESPIRATORY EQUIPMENT INC.

 SAN DIEGO, July 8 /PRNewswire/ -- Dura Pharmaceuticals Inc. (NASDAQ-NMS: DURA) and PARI Werk GmbH and PARI Respiratory Equipment Inc. (PARI), today announced the signing of a letter of intent on the sale of the assets of Dura's device division to PARI. This sale is part of Dura's strategy of concentrating its resources on core, higher-margin prescription respiratory pharmaceuticals.
 The device division's primary products include the Dura-Neb(R) 2000, Dura's portable compressor nebulizer used primarily in delivering solution forms of asthma medications, peak flow meters and two products supplied to Dura by PARI -- the PRONEB(TM) compressor and PARI-JET(TM) Nebulizer System. In connection with the sale, Dura and PARI will terminate their previous distribution agreements. Sales and marketing employees of Dura's device division will be employed by PARI. Dura's dry powder inhaler and portable spirometer, Aspire(R), both under development, are not part of the device division and are not included in the sale agreement.
 The device division, which currently accounts for less than 15 percent of Dura's total sales, has in the past contributed as much as 35 percent of sales but has not kept pace with the company's rapidly growing pharmaceutical division. Dura anticipates deploying the proceeds of the sale into its core business, including investments in its expanding sales force and in its proprietary respiratory products currently under development.
 Cam Garner, Dura's president and chief executive officer, said the agreement is mutually beneficial to both Dura and PARI. "For Dura, the sale will allow us to devote our full attention to the growth and future profitability of our core business. For PARI, which is establishing operations in the U.S., this acquisition will support its entry in the marketplace."
 Werner Gutmann, president of PARI Respiratory Equipment Inc., agreed: "Our acquisition of a viable, existing product line and the addition of the division's sales and marketing organization will enable us to accelerate the development of our U.S. operation," he said. "We recently completed our manufacturing plant near Richmond and anticipate enhanced production efficiencies through this purchase. This agreement also will improve PARI Respiratory Equipment's ability to introduce new products in the U.S.," added Gutmann.
 The closing of the proposed sale is subject to the successful negotiation of a definitive agreement between Dura and PARI as well as the fulfillment of other related contingencies.
 PARI Respiratory Equipment Inc., located in Richmond, Va., is a U.S.-based sister company of PARI Werk GmbH, a private company based in Munich and a major worldwide manufacturer and marketer of nebulizers and other respiratory devices.
 Dura Pharmaceuticals is a San Diego-based developer and marketer of prescription pharmaceutical products, drug delivery systems and medical devices for the treatment of asthma, allergies and related respiratory conditions.
 -0- 7/8/93
 /CONTACT: Cam L. Garner, president and CEO of Dura Pharmaceuticals, 619-457-2553/
 (DURA)


CO: Dura Pharmaceuticals Inc.; PARI Werk GmbH; PARI Respiratory
 Equipment Inc. ST: California IN: MTC SU: TNM


MF-JL -- SD005 -- 9337 07/08/93 08:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 8, 1993
Words:496
Previous Article:QUIDEL AND BECTON DICKINSON EXTEND SUPPLY AGREEMENT BY THREE YEARS
Next Article:CONTINENTAL SAVINGS OF AMERICA ANNOUNCES CONTINUATION OF REAL PROPERTY EARLY DISPOSITION PROGRAM
Topics:


Related Articles
DURA FOCUSES ON DEVELOPMENT OF DRY POWDER INHALER PRODUCTS AND ELECTS TO DISCONTINUE DEVELOPMENT OF PENTYDE PRODUCTS
DURA PHARMACEUTICALS REPORTS CONTINUED RECORD SALES FOR SECOND QUARTER AND FIRST SIX MONTHS OF 1993
DURA PHARMACEUTICALS COMPLETES SALE OF DEVICE DIVISION TO PARI RESPIRATORY EQUIPMENT INC. AND PARI-WERK GmbH
DURA PHARMACEUTICALS AND ELAN CORPORATION ANNOUNCE SIGNING OF DEFINITIVE STOCK PURCHASE AGREEMENT
DURA PHARMACEUTICALS REPORTS EARNINGS FOR SECOND CONSECUTIVE QUARTER ON RECORD SALES
DURA PHARMACEUTICALS, INC., DURA DELIVERY SYSTEMS, INC. AND ELAN CORPORATION, PLC. ANNOUNCE BROAD STRATEGIC ALLIANCE
DURA PHARMACEUTICALS REPORTS FIRST FULL YEAR OF PROFITABILITY FOR YEAR ENDED DEC. 31, 1994
DURA PHARMACEUTICALS ANNOUNCES PROMOTIONS OF ROBERT SCHULTZ AND CLYDE WITHAM TO VICE PRESIDENT
DURA PHARMACEUTICALS SIGNS AGREEMENT TO CO-PROMOTE A NEW RESPIRATORY DRUG WITH KEY PHARMACEUTICALS
DURA PHARMACEUTICALS REPORTS RECORD REVENUES AND EARNINGS FOR THE QUARTER ENDED MARCH 31, 1996

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters